3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Neoplasm Metastasis
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Basal Cell Carcinoma of the Head and Neck
1
Interventions
pembrolizumab
58
Nivolumab
37
aldesleukin
16
Cyclophosphamide
15
atezolizumab
12
Specimen Handling
11
Radiosurgery
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
Ipilimumab
9
Interleukin-2
9
fludarabine
8
fludarabine phosphate
7
Docetaxel
7
Carboplatin
7
avelumab
6
Radiotherapy
6
durvalumab
5
Peripheral Blood Stem Cell Transplantation
5
Immune Checkpoint Inhibitors
5
Cisplatin
5
Bevacizumab
5
tislelizumab
4
temsirolimus
4
spartalizumab
4
Sirolimus
4
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Cryosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
Tissue Banks
×
Dermatologic
×
Clear all
NCT06349642
2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
324 enrolled